AN2 Therapeutics Principal Accounting Officer Sarah Joanne Williams sold 272 shares at $5.53 per share on September 1, 2026. For investors, the disclosed post-sale holding is 66,311 shares, while the transaction price was $5.53 per share in AN2 Therapeutics stock.
Key Highlights
- Sarah Joanne Williams serves as AN2 Therapeutics’ principal accounting officer.
- Williams owned 66,311 AN2 Therapeutics shares after the transaction.
- Sarah Joanne Williams sold 272 AN2 Therapeutics shares at $5.53 per share.
AN2 Therapeutics, Inc. (NASDAQ: ANTX) recorded a 272-share sale by Sarah Joanne Williams at $5.53 per share. The filing identifies Williams as the company’s principal accounting officer.
Williams Retains 66,311 Shares
Williams is AN2 Therapeutics’ principal accounting officer. The transaction took place on September 1, 2026. Following the sale, Williams’ reported ownership stood at 66,311 shares.
FAQs
Q: How many AN2 Therapeutics shares did Sarah Joanne Williams sell?
A: Sarah Joanne Williams sold 272 AN2 Therapeutics shares at $5.53 per share. She was identified as the company’s principal accounting officer.
Q: What was the AN2 Therapeutics stock transaction price?
A: The AN2 Therapeutics transaction was priced at $5.53 per share. The filing states that the sale occurred on September 1, 2026.
Q: How many AN2 Therapeutics shares did Williams own afterward?
A: Sarah Joanne Williams owned 66,311 AN2 Therapeutics shares after the transaction. The filing identifies Williams as the company’s principal accounting officer.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.